Gemtuzumab ozogamicin in combination with vorinostat and azacitidine in older patients with relapsed or refractory acute myeloid leukemia: a phase I/II study.
Walter, Roland B; Medeiros, Bruno C; Gardner, Kelda M; Orlowski, Kaysey F; Gallegos, Leonel; Scott, Bart L; Hendrie, Paul C; Estey, Elihu H.
; 99(1): 54-9, 2014 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-24142996
Lifting the Differentiation Embargo.
CpG Island Hypermethylation Mediated by DNMT3A Is a Consequence of AML Progression.
Data-Driven Phenotypic Dissection of AML Reveals Progenitor-like Cells that Correlate with Prognosis.
Single-Cell RNA-Seq Reveals AML Hierarchies Relevant to Disease Progression and Immunity.
Genomic Classification and Prognosis in Acute Myeloid Leukemia.
Effective Murine Model Induction for Niche Study in Immune Cells Against Leukemia.
Immune Escape of AML Cells after Transplantation. Reply.
How to predict the future.
Midostaurin added to chemotherapy and continued single-agent maintenance therapy in acute myeloid leukemia with <i>FLT3</i>-ITD.
[Genetic characteristics and clinical outcomes of pediatric acute myeloid leukemia with NUP98-NSD1 fusion gene].